Thus, natural variation in GABRA2 expression may contribute to variable expressivity of Dravet syndrome and other epilepsy phenotypes, and possibly contribute to treatment response for drugs that target GABAA receptors. This evidence concerns the gene GABRA2 and epilepsy.